GHRP-6 research and evidence overview

GHRP-6's core human pharmacology was characterised carefully more than three decades ago, and the numbers are precise. A single intravenous dose produces a large, dose-dependent growth hormone spike in healthy men. The same study documented something less often quoted: at the highest dose tested, prolactin and cortisol also rose roughly two-fold. Beyond those acute endocrine studies, the human record is empty — no trial of repeated dosing, no body-composition or performance endpoint, no long-term safety data. GHRP-6's historical importance is that it helped reveal a hormone system nobody knew existed.

The defining human study administered the synthetic hexapeptide His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂ — GHRP-6 — to 18 normal men by intravenous bolus at 0.1, 0.3, and 1.0 µg/kg, alongside GH-releasing hormone as a comparator, with prolactin, LH, TSH, and cortisol measured to test specificity (Bowers et al., Journal of Clinical Endocrinology & Metabolism 1990;70(4):975–982, PMID 2108187).

Mean peak serum GH after placebo and the three ascending doses was 1.2 ± 0.3, 7.6 ± 2.5, 16.5 ± 4.1, and 68.7 ± 15.5 µg/L respectively — a clean, steep dose-response. No adverse clinical effects or laboratory abnormalities were observed in response to GHRP-6.

The specificity result deserves equal billing. Serum prolactin and cortisol rose about two-fold above baseline at the 1.0 µg/kg dose — the same dose that produced the impressive GH figure. LH and TSH did not change over the first hour. In other words, the strongest GH response came with off-target hormonal effects, which is a property of the compound rather than an incidental observation.

The study's more consequential result was mechanistic. Submaximal doses of GHRP-6 (0.1 and 0.3 µg/kg) combined with GHRH 1 µg/kg stimulated GH release synergistically — more than either agent's contribution alone.

Synergy implied the two peptides act through independent pathways, which is what led the authors to conclude that GHRP's activity reflected "a new physiological system in need of further characterization." They were right. The receptor GHRP-6 acts on was later identified as the growth hormone secretagogue receptor, and the search for its natural ligand led to the discovery of ghrelin in 1999. GHRP-6's real scientific legacy is that it was the probe that exposed an entire hormone axis — which is a different kind of significance from being a validated therapy.

A separate line of GHRP-6 research, run largely by Cuban groups and their collaborators, has pursued cytoprotection rather than growth hormone. A 2026 study in International Immunopharmacology tested GHRP-6 in mouse models of acute lung injury induced by intratracheal lipopolysaccharide or zymosan plus platelet-activating factor (Wang et al., PMID 41534456). In the acute phase GHRP-6 reduced neutrophilic alveolitis, attenuated loss of lung compliance, improved alveolar-capillary permeability, and lowered serum interleukin-1β; at 28 days it preserved lung parenchymal integrity with less collagen accumulation. The authors describe it as the first assessment of GHRP-6 in a lung damage model.

That work is mouse-only, and it explores effects the GH-release mechanism would not predict — a reminder that this receptor is expressed well beyond the pituitary. It has not produced a human trial.

Nothing in the published human literature addresses the reasons people actually use GHRP-6:

• No randomised trial of repeated dosing with any clinical endpoint.
• No lean mass, fat mass, strength, recovery, or sleep outcomes.
• No data past acute administration — so no evidence on whether the GH response persists or attenuates with regular use.
• No long-term safety record covering insulin sensitivity, glucose tolerance, or chronic IGF-1 elevation.
• The appetite effect characteristic of this receptor class was not the focus of the 1990 study, but it is well documented for its close relative GHRP-2 in humans.

GHRP-6 is not FDA-approved for any use and is prohibited in sport by the World Anti-Doping Agency. A 2026 review of the direct-to-patient peptide market places growth hormone secretagogues among compounds where patient self-administration has substantially outrun the clinical evidence (Frontiers in Endocrinology 2026, PMID 42395176). The demonstrated fact is that GHRP-6 raises GH acutely; everything downstream of that remains untested.